Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2012-03-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT01484600
Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT01459796
Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol
Phase 4
Completed
- Conditions
- Intercritical Gout
- Interventions
- First Posted Date
- 2011-10-14
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 82
- Registration Number
- NCT01451645
Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2011-06-30
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT01385657
Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema
Phase 3
Completed
- Conditions
- Diabetic Macular Edema
- Interventions
- Procedure: Macular Laser PhotocoagulationDrug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 466
- Registration Number
- NCT01363440
Study of Nesvacumab (REGN910/ SAR307746)
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 53
- Registration Number
- NCT01271972
Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 77
- Registration Number
- NCT01266876
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
Phase 1
Completed
- Conditions
- Dermatitis
- Interventions
- Biological: REGN668
- First Posted Date
- 2010-12-14
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT01259323
A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee
Phase 2
Withdrawn
- Conditions
- Osteoarthritis
- Interventions
- Biological: REGN475Other: Placebo
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT01239017
Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: REGN846
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT01209793
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Australia
© Copyright 2025. All Rights Reserved by MedPath